

SAVE-THE-DATE

Advances in the Diagnosis & Treatment of Hodgkin Lymphoma (HL) & Systemic Anaplastic Large Cell Lymphoma (sALCL)

27 March 2014 (Thursday), Hotel Pullman Kuala Lumpur Bangsar



Peter Borchmann is Assistant Medical Director in the Department of Hematology / Oncology at the University Hospital of Cologne. He is also Study Secretary of the German Hodgkin Study Group (GHSg). His scientific focus is the development of immunotherapy in Hodgkin Lymphoma, as well in preclinical as in clinical investigations. Within the GHSg, he is leader of the working group "Survivorship" and responsible for the development and conduct of clinical studies for advanced stage HL and elderly patients. He is member of the American Society of Hematology and the German Society of Haematology and Oncology.

Registration Deadline: 17th March 2014

Kindly contact the event organizer, Apxara Travel & Events.

Contact Person : Ms. Josalena

Tel no. : +603 7957 6866

Email : josalena@apxara.com

Time	Topic	Presenter
1630 – 1715	REGISTRATION and Welcome High Tea	All
1715 – 1730	Opening Address by Chairperson	Dr. Leong Kin Wah Consultant Haemato-Oncologist (GlenEagles Penang)
1730 – 1745	Welcome & Introduction to Takeda Oncology Objective of this workshop	Dr. Dirk Weber Emerging Market Medical Director Oncology (Takeda Switzerland)
1745 – 1800	Hodgkin Lymphoma Overview	Dr. Vikram Shetty Regional Medical Advisor Oncology (Takeda Singapore)
1800 – 1820	Prevalence of Hodgkin Lymphoma in Malaysia	Dr. Tan Sen Mui Consultant Haematologist (Hospital Ampang)
1820 - 1840	Diagnosis & Management of Hodgkin Lymphoma in Malaysia	Prof. Dr. S Fadilah S Abdul Wahid Senior Consultant Haematologist & Transplant Physician, Head of Cell Therapy Centre, (UKM Medical Centre)
1840 – 1850	Q& A	<i>Moderated by</i> Dr. Leong Kin Wah
1850 – 1910	Introduction to brentuximab	Prof. Peter Borchmann
1910 – 1940	BREAK	All
1940 – 2010	Management of Patients with Relapse / Refractory Hodgkin Lymphoma focus on brentuximab data	Prof. Peter Borchmann Study Secretary of the German Hodgkin Study Group (GHSg)
2010 – 2020	Brentuximab in sALCL	
2020 – 2030	Q & A	<i>Moderated by</i> Dr. Leong Kin Wah & Dr. Vikram Shetty
2030 onwards	DINNER	All

Event jointly organized by:



FNP-ONC-002-FEB-2014